Drug Profile
ISIS 16009
Latest Information Update: 05 Sep 2002
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Bcl-X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer